PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
61.53%
Cash & equivalents growing 61.53% while CRVO's declined -39.57%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
61.53%
Below half of CRVO's -12.33%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.75%
Below half of CRVO's -13.08%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
529.47%
Higher PP&E (Net) Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
588.21%
Higher Total Non-Current Assets Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
63.35%
Below half of CRVO's -13.08%. Michael Burry sees a potential red flag for stagnation or capital shortage.
9.62%
Above 1.5x CRVO's 4.04%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
59.49%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
103.88%
Higher Deferred Revenue (Current) Growth compared to CRVO's zero value, indicating better performance.
-531.94%
Exceeding 1.5x CRVO's -42.17%. Michael Burry suspects ballooning short-term obligations vs. competitor.
9.77%
Less than half of CRVO's -14.91%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1866750.00%
Higher Total Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
661.90%
Less than half of CRVO's -14.91%. David Dodd sees far fewer liability expansions relative to competitor.
13.64%
Higher Common Stock (Book Value) Growth compared to CRVO's zero value, indicating worse performance.
-2.98%
Similar yoy to CRVO's -3.11%. Walter Schloss sees parallel earnings retention vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.57%
Below half CRVO's -12.90%. Michael Burry sees potential underperformance in building shareholder capital.
63.35%
Below half CRVO's -13.08%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
1244.16%
Higher Total Debt Growth compared to CRVO's zero value, indicating worse performance.
-58.28%
Less than half of CRVO's 39.57%. David Dodd sees better deleveraging or stronger cash buildup than competitor.